Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                News & Events for Human Drugs

News & Events for Human Drugs

                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective Home
          Drugs
          News & Events for Human Drugs
          Bridging Efficacy and Safety to the Obese: Considerations and Scientific Approaches - 11/09/2022News & Events for Human Drugs Virtual
    Event Title
              Bridging Efficacy and Safety to the Obese: Considerations and Scientific Approaches


                  November 9, 2022

  

    
  Share
    Post
    Linkedin

    Email
    PrintOn This Page
      Meeting InformationDate:
          
  


     
           

November 9, 2022   

 
 
        
                                      Time: 
                                      
8:30 AM
    - 4:15 PM
ET

 





Slides and Videos

About this Virtual Workshop:

The U.S. Food and Drug Administration (FDA) in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) will host a one-day virtual public workshop entitled “Bridging Efficacy and Safety to the Obese: Considerations and Scientific Approaches” on November 9, 2022. The purpose of this workshop is to review the implications of obesity in adult and pediatric patients on safety, efficacy, drug dosing and disposition.

Besides the major health and socioeconomic implications of obesity, there are great challenges in ensuring the optimal use and development of drugs for the growing population of obese persons. Obese patients are a large segment of the U.S. population and should be included in drug development studies. There are presently no clear dosing guidelines for obese pediatric patients. Although smaller clinical studies have begun to examine drug pharmacokinetics in obese pediatric patients, the relationship between pediatric obesity and drug response, including efficacy and safety, has not been thoroughly elucidated. Advancing this field requires identifying key knowledge gaps and barriers to the conduct of such studies and potential innovative solutions to improve data generation and analysis.

Workshop Objectives:

1. Review the implications of obesity in adult and pediatric patients on safety, efficacy, drug dosing and disposition.

2. Discuss:

(a) If adult and pediatric patients should be identified and studied as a special population in new drug development programs.
(b) When it may be appropriate to include obese patients in drug development studies to develop specific dosing guidelines for obese patients.

Meeting Information and Registration:

This virtual workshop is open to the public with no cost to attend, but registration is required.

For more information and to view the draft Agenda, visit the MCERSI Webpage.

**Contact:**

For questions regarding this event, please contact:

Althea Cuff
Office of Clinical Pharmacology
Center for Drug Evaluation and Research
U.S. Food and Drug AdministrationOCPWorkshops@fda.hhs.gov

                                                                                  Content current as of:
      12/12/2022
         
                   
Regulated Product(s)
		 DrugsMore Meetings,
      Conferences, and
      Workshops
        
        News & Events for Human Drugs

          
                        CDER Conversations
          Q&A with FDA
          Spotlight on CDER Science


                        From Our Perspective
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop